Analysis of Rituximab intensification therapy for low grade B-cell lymphoma refractory to Bendamustine

Analysis of Rituximab intensification therapy for low grade B-cell lymphoma refractory to Bendamustine - Bendamustine intensification therapy for low grade B-cell lymphoma refractory to Bendamustine

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007110

Enrollment

Registered

2012-01-27

Start date

2012-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

low grade B-cell lymphoma

Interventions

Rituximab intensification in case of partial response or stable disease observation in case of complete remission

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Relapse and refractory low grade B-cell lymphoma patients who will be treated with Bendamustine. Their hepatic and renal functions should be normal.

Exclusion criteria

Exclusion criteria: 1. for whom Bendamustine is contraindication 2. with liver cirrhosis 3. with severe mental disability 4. pregnant or possible to be pregnant

Design outcomes

Primary

Measure	Time frame
response ratio	—

Secondary

Measure	Time frame
progression free survival and safety	—

Countries

Japan

Contacts

Public ContactYoichi Imai

Tokyo women's medical university department of hematology

imaiyo@dh.twmu.ac.jp03-3353-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026